0000899243-19-028978.txt : 20191211 0000899243-19-028978.hdr.sgml : 20191211 20191211194047 ACCESSION NUMBER: 0000899243-19-028978 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191210 FILED AS OF DATE: 20191211 DATE AS OF CHANGE: 20191211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANIA EDWIN M JR CENTRAL INDEX KEY: 0001255927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 191280794 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-10 0 0001682852 Moderna, Inc. MRNA 0001255927 KANIA EDWIN M JR C/O FLAGSHIP PIONEERING, INC. 55 CAMBRIDGE PARKWAY, SUITE 800E CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2019-12-10 4 S 0 100000 18.8084 D 498847 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.75 to $18.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 1. Edwin M. Kania, Jr. is filing this report as a 10% stockholder as a result of his relationship with the Flagship Entities (defined below), which collectively hold more than 10% of the shares of the Issuer. 2. This report relates solely to the personal transactions in the shares of the Issuer by Edwin M. Kania, Jr. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), which is the general partner of each of Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. (the "Flagship IV Funds" and, together with Flagship Fund IV GP and Flagship Pioneering, Inc., the "Flagship Entities"). While Mr. Kania is retired from Pioneering, he continues to serve as a manager of Flagship Fund IV GP. The Flagship Entities together with Dr. Afeyan and Mr. Kania, file separate Section 16 reports disclosing the extent of Mr. Kania's Section 16 beneficial ownership in transactions by the Flagship Entities. Edwin M. Kania, Jr. By: /s/ Edwin M. Kania, Jr. 2019-12-11